Τίτλος:
Vitamin D supplementation in patients with diabetes mellitus type 2 on
different therapeutic regimens: a one-year prospective study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Little or no research has determined the effect of vitamin
D3 supplementation in conjunction with pharmacological and
non-pharmacological approaches in the diabetes mellitus type 2 (DMT2)
patients. The objective of this study was to determine the effect of
vitamin D3 supplementation in a cohort of Saudi DMT2 population on diet,
insulin and/or different oral hypoglycemic agents and compare them with
a non-DMT2 control cohort.
Methods: A total of 499 randomly selected Saudi subjects divided into 8
groups [Non-DMT2 Control = 151; Rosiglitazone alone = 49; Diet = 15;
Insulin alone = 55; Insulin + Orals = 12; Metformin alone = 121; Oral
agents combination = 37; Sulphonylurea alone = 59] were included in this
12-month interventional study. All DMT2 patients were given 2000 IU
vitamin D3 daily, while the control group received none but were advised
to increase sun exposure. Anthropometrics, glucose, lipid profile and
25-hydroxyvitamin D (25-OHVitD) were measured at baseline, 6 and 12
months.
Results: Circulating 25-OHVitD concentrations improved in all patient
groups. The metformin group showed the highest change in circulating
vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as
compared to baseline (p < 0.001). No significant changes were observed
in the BMI and glucose in any of the DMT2 groups. In contrast, the
insulin + oral agents group showed more significant improvements in the
metabolic profile, which included triglycerides and total cholesterol,
as well as systolic blood pressure and HDL-cholesterol in males. Also,
significant decreases in triglycerides were observed in the
rosiglitazone and insulin + oral hypoglycemic agent groups both at 6 and
12 months of supplementation (both p-values <0.001).
Conclusion: While in all DMT2 groups circulating levels of 25-OHVitD
increased after supplementation, in DMT2 patients on insulin in
combination with other drugs benefitted the most in improving
cardiovascular risk. Metformin improves 25-hydroxyvitamin D levels but
did not seem to confer other added cardiometabolic benefits.
Συγγραφείς:
Alkharfy, Khalid M.
Al-Daghri, Nasser M.
Sabico, Shaun B. and
Al-Othman, Abdulaziz
Moharram, Osama
Alokail, Majed S. and
Al-Saleh, Yousef
Kumar, Sudhesh
Chrousos, George P.
Περιοδικό:
Cardiovascular Diabetology
Εκδότης:
BioMed Central Ltd.
Λέξεις-κλειδιά:
Vitamin D; Vitamin D supplementation; Diabetes mellitus; Anti-diabetes
therapies
DOI:
10.1186/1475-2840-12-113
